Our Story

Our Story

As the global leader in orthopedic hyaluronic acid (HA)-based regenerative and osteoarthritis (OA) pain management solutions, our goal is to redefine what’s possible with hyaluronic acid. For more than 30 years, we’ve pioneered HA innovation. From design and development to manufacturing and global commercialization, our commitment has remained clear: help people restore active living.

We partner closely with clinicians to create highly differentiated, science-driven products to improve patient outcomes. Our passion for innovation continues to drive us, delivering regenerative technologies that empower movement and enhance people’s lives worldwide.

We are driven by purpose and powered by science.

Explore some of our milestones

Our rich history of proven expertise has formed who we are today.

  1. 2025
    • Received 510(k) clearance for two larger Integrity™ implant sizes: 25x60mm and 40x60mm
    • Submitted the final module for Hyalofast® Premarket Approval (PMA) to the US FDA
    • Completed the divestiture of Parcus Medical to Medacta Group SA
  2. 2024
    • Commenced full market release of the Integrity Implant System
    • Completed the divestiture of its Arthrosurface business to Phoenix Brio, Incorporated
  3. 2023
    • Received 510(k) clearance for the Integrity Implant System, a regenerative hyaluronic acid-based scaffold for rotator cuff and other tendon repairs, along with its complete arthroscopic instrumentation platform; commenced limited market release after performing first surgeries
    • Completed enrollment in Hyalofast pivotal Phase III clinical study, a key milestone in its path to achieving US FDA approval
    • Tactoset® received additional FDA 510(k) clearance to be combined with autogenous bone marrow aspirate (BMA)
  4. 2022
    • Received the ACE Award for cutting-edge innovation from the American Orthopedic Society for Sports Medicine (AOSSM) for Tactoset Injectable Bone Substitute for hardware augmentation
    • Cingal® successfully achieved its primary endpoint in its third Phase III clinical trial
  5. 2021
    • FDA 510(k) clearance received for Tactoset Injectable Bone Substitute to include a new indication for augmentation of hardware, including suture anchors
    • Competed enrollment for US pilot clinical study of Cingal, a combination hyaluronic acid (HA) and fast-acting steroid injection for osteoarthritis knee pain
  6. 2020
    • Anika acquired Arthrosurface, a leading, privately-held provider of joint preservation solutions, and Parcus Medical, a leading, privately-held sports medicine company
  7. 2019
    • Tactoset, a surgically delivered therapy for insufficiency fractures, was launched in the United States
  8. 2018
  9. 2017
    • FDA 510(k) clearance received for HA-enhanced Tactoset Injectable Bone Substitute for the treatment of insufficiency fractures
  10. 2016
    • International launch of Cingal, the first HA-based viscosupplement plus steroid combination product for the treatment of osteoarthritis pain
    • CE Mark approval received for Orthovisc®-T, a treatment designed to relieve pain and restore function for patients with chronic tennis elbow
  11. 2015
    • A larger 5x5cm Hyalofast® scaffold to treat large cartilage defects was introduced internationally
  12. 2014
    • FDA approval and launch of Monovisc, the first non-animal sourced hyaluronic acid single-injection treatment for knee osteoarthritis in the United States
  13. 2012
    • Orthovisc achieved #1 U.S. market leader position in the multi-injection viscosupplement market
    • First procedure performed using NanoFx®, an improved microfracture solution compared to the standard marrow-based regenerative technique
  14. 2011
    • Established a marketing and distribution relationship with Johnson & Johnson to sell Monovisc ahead of its approval in 2014
  15. 2009
    • Acquired technology used in Hyalofast, a one-step cartilage regeneration product, through the strategic acquisition of Fidia Advanced Biopolymers, a leading innovator in hyaluronic acid-based tissue engineered products, based in Abano Terme, Italy
    • Hyalofast received CE mark approval and launched internationally
  16. 2007
    • CE mark approval received for Monovisc in Europe
  17. 2004
    • Obtained FDA approval for and launched Orthovisc in the United States
  18. 2003
    • Established a marketing and distribution relationship with Johnson & Johnson to sell Orthovisc in the United States once approved by the FDA
  19. 1996
    • Received CE mark approval for and launched Orthovisc internationally, the company’s first HA-based viscosupplement used for the treatment of osteoarthritis pain
  20. 1995
    • Signed a distribution agreement with Boehringer Ingelheim Vetmedica, a partnership that has continued to this day, for Hyvisc®, a hyaluronic acid equine osteoarthritis product
  21. 1992
    • Anika Therapeutics was incorporated as a spin-off of MedChem Products, Inc
    • Signed an agreement with Johnson & Johnson to manufacture and supply its hyaluronic acid-based ophthalmic products, Amvisc® and Amvisc® Plus